Home
Storia in 2 fonti
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
- ·
ft.com
Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid
Novo and Metsera deny Pfizer’s arguments
- ·
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies
Improved pitches from both large pharma groups expected to be revealed later on Tuesday
- ·
cnbc.com
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
- ·
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
- ·
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
- ·
There is only one winner in the Pfizer Novo Nordisk showdown
Fight for Metsera looks like 1980s corporate raider redux
- ·
US regulator warns Novo Nordisk’s Metsera offer ‘may violate’ antitrust law
Federal Trade Commission wants to ensure bid for weight-loss biotech addresses competition concerns
- ·
Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
- ·
US to slash prices of obesity drugs offered on Trump website
White House’s landmark deal with Novo Nordisk and Eli Lilly will cut costs from at least $1,000 to about $350
- ·
Pfizer wins $10bn bidding war for weight-loss start-up Metsera
Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns